首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

2150649

循環性腫瘤細胞市場報告：趨勢、預測與競爭分析（至2035年）

Circulating Tumor Cell Market Report: Trends, Forecast and Competitive Analysis to 2035

出版日期: 2026年10月15日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

循環性腫瘤細胞市場

全球循環性腫瘤細胞市場前景廣闊，預計將在醫院、診所、診斷中心以及科學研究和學術機構等領域帶來許多機會。全球循環性腫瘤細胞市場預計將從2027年的180億美元成長至2035年的490億美元，2027年至2035年的複合年成長率（CAGR）為13.9%。推動市場成長的關鍵因素包括：對癌症早期檢測需求的不斷成長、液態生物檢體技術的日益普及以及對個人化癌症治療的日益重視。

根據 Lucintel 的預測，在預測期內，試劑盒和試劑預計將在產品類型中實現最高的成長率。這是因為試劑盒和試劑的使用頻率較高，成本效益是其首要考慮因素。
從最終用途來看，「研究和學術機構」預計將在預測期內呈現最高的成長，因為腫瘤學研究活動擴大由學術機構進行。
從區域來看，由於腫瘤學研究預計將獲得資金支持以及液態生物檢體技術將取得進步，預計北美在預測期內將呈現最高的成長率。

循環性腫瘤細胞市場的新趨勢

癌細胞技術目前主要用於基礎研究，預計在2025年至2027年間過渡到臨床應用。在此期間，Lucintel指出，液態生物檢體、癌症治療評估和生物標記發現是關鍵的市場促進因素。檢測靈敏度的提高、更完善的保險報銷以及醫療專業人員對微創癌症切片檢查方法的偏好將是主要驅動力。

臨床證據：到2025年，更多研究結果將表明，血液中循環性腫瘤細胞的定量分析能夠預測疾病預後，並與治療反應相關。美國食品藥物管理局（FDA）已批准將「細胞搜尋」（Cell Search）技術用於轉移性乳癌、前列腺癌和大腸癌的診斷。未來3至5年內獲得的更多具有臨床意義的數據將有助於該技術融入腫瘤科的常規診療實踐。
分析限制：單細胞/分子技術不斷進步，在未來幾年，預計多項結合物理和分子技術的研究將捕獲癌細胞並提高癌細胞檢測的靈敏度。
多組體學整合：到2025年，計畫進行研究，將循環腫瘤DNA、RNA和蛋白質訊號與循環性腫瘤細胞整合。預計這將使研究人員能夠建立更全面的生物標記物，從而有助於患者分層和選擇合適的治療方案。
工作流程自動化和標準化：檢查室持續推進檢測自動化和工作流程標準化，可望提高診斷測試的一致性並提升檢測能力。此外，這些平台和工作流程的自動化也將減少檢查室人員需求。預計從2025年到2027年，診斷產業將受益於工作流程的改進和一致性的提高。
專業化：2020年至2025年，診斷公司應專注於證明其診斷方法的臨床效用，以確保獲得保險報銷。腫瘤市場預計將繼續為實現這一目標提供機會。

如果能夠獲得證據支持特定疾病診斷測試的臨床效用，循環性腫瘤細胞診斷技術的廣泛應用就成為可能。這類證據可以透過診斷、製藥和臨床領域的研究人員之間的合作研究來獲得。

循環性腫瘤細胞（CTC）市場最新趨勢

循環性腫瘤細胞(CTC) 市場正從研究應用轉向臨床應用，尤其是在癌症治療方案的選擇和後續觀察。預計最大的發展將發生在 2020 年至 2025 年間。 Lucintel 預測，隨著 CTC 檢測的自動化和保險覆蓋的實現，未來幾年該市場將持續擴張。

策略夥伴關係：正如 Menarini 與幾家領先的病理實驗室在 2025 年 3 月達成的夥伴關係所表明的那樣，CTC 檢測的標準化將導致臨床應用增加，並促成長期合約的簽訂。
技術介紹：正如 Recite 在 2025 年 6 月宣布的那樣，CTC 檢測的自動化和處理能力將顯著提高 CTC 檢測的成本效益，並將這項技術的應用範圍擴大到主要醫療中心以外的地區。
臨床協議：正如 Epic Sciences 在 2025 年 9 月宣布的那樣，隨著主要製藥公司採用 CTC 檢測來監測癌症治療的效果，CTC 檢測的接受度將會增加。
生產擴張：正如美納里尼公司在 2026 年 1 月宣布的那樣，隨著產量的持續成長，CTC 檢測的整體供應將會改善。
政府批准：進入2026年，監管機構對液態生物檢體的申請資料，包括支持腫瘤學中循環腫瘤細胞（CTC）終點的證明文件，表現出更積極的態度。如果這種趨勢持續下去，美國醫療保險和醫療補助服務中心（CMS）關於液態生物檢體的核准流程將更加清晰，從而降低申辦方的風險，並可能有助於保險報銷談判。

CTC分析儀已從資本設備模式轉向服務模式。近年來，臨床試驗申辦單位已成為CTC檢測的主要市場。在醫院環境中，CTC檢測的採用和報銷取決於癌症類型和支持該檢測的證據。採用自動化和集中化技術並提供多種檢測項目的實驗室將提高盈利。為了在未來幾年取得成功，供應商需要超越簡單的CTC計數，將CTC檢測整合到癌症治療決策流程中。提供此類整合將賦予他們永續的競爭優勢。技術創新將變得不再那麼重要。在未來幾年，這項技術將主要用於支持新型抗癌藥物的研發。

The future of the global circulating tumor cell market looks promising with opportunities in the hospital & clinic, diagnostic center, and research & academic institute markets. The global circulating tumor cell market is expected to reach an estimated $49 billion by 2035 from $18 billion in 2027 with a CAGR of 13.9% from 2027 to 2035. The major drivers for this market are he increasing demand for early cancer detection, the rising adoption of liquid biopsy techniques, and the growing focus on personalized cancer treatments.

Lucintel forecasts that, within the product category, kits & reagents is expected to witness the highest growth over the forecast period due to kits and reagents are consumed repeatedly and cost efficiency is prioritized.
Within the end use category, research & academic institutes is expected to witness the highest growth over the forecast period due to oncology research activities are increasingly undertaken by academic institutions.
In terms of regions, North America is expected to witness the highest growth over the forecast period due to financing for oncology research and advances in liquid biopsies is available.

Emerging Trends in Circulating Tumor Cell Market

Tumour cell technology has predominantly been used in basic research and is expected to transition towards clinical use around 2025 to 2027. During this period, Lucintel anticipates that the major market drivers will be liquid biopsies, cancer treatment evaluation, and biomarker discovery. Improved sensitivity of assays, better reimbursement, and the preference of healthcare professionals to use less invasive cancer biopsy methods will be the major drivers.

Clinical Evidence: In 2025, additional studies demonstrated that quantification of circulating tumour cells in the blood is predictive of disease prognosis, and correlated with therapy response. The FDA cleared use of the Cell Search technology for the diagnosis of metastatic breast cancer, prostate cancer and colorectal cancer. In the next 3 to 5 years, further clinically relevant data will facilitate the incorporation of this technology into routine oncology practice.
Analytical Limitations: Single cell/molecular technologies continue to improve, and in the next few years, multiple studies will use a combination of physical and molecular technologies to capture cancer cells to improve the sensitivity of tumour cell detection.
Multi-omics Integration: In 2025, studies plan to integrate circulating tumour DNA, RNA, and protein signals, along with circulating tumour cells. This allows researchers to create more comprehensive biomarkers, and should help researchers better stratify patients and select appropriate therapies.
Automation and Standardization of Workflows: Continuous efforts toward the automation of laboratory assays and standardization of laboratory workflows should improve the consistency of diagnostic tests and increase the throughput of laboratory assays. Furthermore, the automated nature of these platforms and workflows should reduce the personnel requirements of a laboratory. The diagnostic industry should benefit from improved workflows and consistency during the 2025-2027 timeframe.
Specialization: From 2020 to 2025, the focus of diagnostic companies should be on establishing evidence of the clinical utility of their diagnostics in order to gain reimbursement. The oncology market should continue to provide opportunities to meet this goal.

Evidence that supports the clinical utility of a diagnostic test for a specific condition should enable the widespread adoption of circulating tumour cell diagnostics. Evidence may come from collaborations among diagnostic, pharmaceutical, and clinical researchers.

Recent Developments in the Circulating Tumor Cell Market

The market for circulating tumour cells (CTCs) is shifting from research to clinical use, specifically for selecting cancer treatments and monitoring tumors over time. The most significant advances are expected to occur between 2020 and 2025. Lucintel anticipates that in the subsequent years, the market will continue to progress as the automation and reimbursement of CTC tests becomes a reality.

Strategic Partnership: The standardization of CTC tests, as evidenced by the partnerships between Menarini and several major pathology laboratories in March 2025, will lead to wider clinical use and longer-term contracts.
Technology Launches: A considerable increase in the automation and throughput of CTC tests, as announced by Recite in June 2025, will favourable impact the economics of CTC tests and increase access to the technology beyond major medical centres.
Clinical Contracts: The selection of CTC tests by major pharmaceutical companies to monitor the effectiveness of cancer therapies, as announced by Epic Sciences in September 2025, will lead to improved acceptance of CTC tests.
Production Expansion: The continuous increase in the production of CTC tests, as announced by Menarini in January 2026, will improve the overall supply of CTC tests.
Government Approvals: Regulatory bodies have been more amenable to liquid biopsy dossiers in 2026, including dossiers supporting CTC endpoints in oncology. Continued progress will likely lead to clarification of CMS approval processes for liquid biopsy and reduced risk for sponsors, facilitating reimbursement negotiations.

The CTC analyser has transitioned to a service model from a capital instrument model. Sponsors of clinical trials have recently been the primary market for CTC testing. In the hospital setting, the adoption and reimbursement of CTC testing is variable based on the cancer type, and the evidence supporting the test. Laboratories that incorporate automation and centralization and offer multiple assays will increase profitability. In the coming years, vendors will be successful if they integrate CTC testing to aid in the decision-making process for cancer treatment rather than providing CTC counts in isolation. Offering such integration will provide a sustainable competitive edge. Novelty of the technology will be of lesser importance. In the coming years, the technology will primarily be used to support the development of new oncology drugs.

Strategic Growth Opportunities in the Circulating Tumor Cell Market

The market for products and services cantered on circulating tumour cells (CTCs) is transitioning from early-stage research to clinical applications. From 2024 to 2026, anticipate first commercial sales for use cases including precision cancer therapy and monitoring therapy resistance. Additionally, expect sales from laboratory testing performed at remote patient locations. In the medium to long-term, the market is expected to expand as the body of supporting clinical evidence grows and pharmaceutical companies use CTC assays to select cancer patients for therapeutic management.

Therapy Response Monitoring: Pharmaceutical companies will also be interested in CTC analysis as they evaluate the efficacy of their cancer therapies. Positive evidence from therapy monitoring studies has the potential to catalyze further interest from the pharmaceutical industry. Sponsored evidence is likely to increase, particularly if studies demonstrate a positive impact on patient management.
Clinical Trials: The results of CTC analysis can also aid in the enrolment and stratification of clinical studies. Furthermore, CTC analysis may aid in the understanding of mechanisms of therapy resistance.
Single-cell Molecular Profiling: As of June 2025, single-cell assays primarily analysed less than ten cells from patient samples. However, the growth of this technique will allow for the characterization of rare cells, and assist oncologists in developing personalized therapies and understanding mechanistically why some cancers become drug resistant.
Decentralized Oncology Testing: The development of hand-held cancer tests, along with improvements in other non-communicable disease diagnostic tests, will lead to an increased demand for rapid, point-of-care diagnostics in the next five to seven years.
Companion Diagnostics: Companies focusing on circulating tumour cells (CTCs) will have the opportunity to develop other companion diagnostics in conjunction with pharmaceutical companies. In the long-term, liquid biopsies will be commercially competitive against traditional tissue biopsies.

The largest challenge for the broad market adoption of CTC assays is reimbursement. In oncology, standardization of CTC assays will allow the broad adoption of CTC testing. CTC assays will allow researchers to understand the biology of tumors and their metastasis. Focused efforts to establish assay utility in specific cancers will yield the best market opportunity. Long term, CTC companies will thrive if they establish a repeatable, reimbursement-protected customer base for advanced molecular testing for oncology.

Circulating Tumor Cell Market Drivers and Challenges

The increasing incidence of cancer drives the need for advanced cancer monitoring. Along with this, the desired monitoring should be less invasive for the patient and easier for the practitioner. Newer technologies in the field of circulating tumour cell (CTC) analysis enable the capture of cancer cells in the blood and facilitate decision-making in-patient management. Limitations in CTC test reimbursement and adoption are expected to ease with improvements in the standardization of the tests and CTC assay automation.

The factors responsible for driving this market include:

Rising Customer Interest: With the advantages of CTC technology, hospitals and laboratories are investing in CTC analysis to aid in the prognosis and management of cancer patients. The American Cancer Society's report (Jan 2025) projected approximately 2.04 million cancer cases for 2025 in the U.S. With these increasing numbers, hospitals and research facilities are expected to intensify efforts to develop more effective cancer management strategies, including the use of CTC testing.
Technology: Technology has improved in microfluidics, imaging, artificial intelligence, and other areas related to molecular characterizations. Single cell sequencing has improved the analysis of CTCs. In 2025, research platforms had the ability to simultaneously analyse cellular information and mutations relating to cancer and other targets of treatment. Continued integration of automation and instruments would eliminate the variability between laboratory personnel and improve the overall efficiency of a laboratory. It is anticipated that in the next 3 to 5 years, advanced platforms would enable the real time assessment of cancer cells and their response to various therapies.
Regulatory: Various regulatory agencies have introduced or modified policies relating to personalized medicine, companion diagnostics and laboratory developed tests. In 2025, Europe and other regions enforced the EU In-vitro diagnostic (EU IVD) directive. The directive increased the burden on diagnostic laboratories to validate their tests, but brought regulatory certainty and confidence to the diagnostic industry. The Enhanced policies would facilitate the establishment of standard tests by diagnostic companies and encourage collaboration between the diagnostic and pharmaceutical industries.
Product Innovation: Currently, manufacturers are combining multiple downstream assays into a single workflow. For example, they are integrating cellular assays for enrichment, enumeration and imaging with molecular assays and digital readouts. Our sponsored research in September 2025 showed that the field of oncology is focusing on the use of multiplexed tumour markers, as opposed to relying on absolute numbers of circulating tumour cells. The usage of multimarket panels allows for classification of tumour subtypes and selection of personalized therapies. As the volume and complexity of clinical assays continue to increase, innovative products need to be developed to address the challenge of performing multiple clinical assays using limited volumes of patient blood. There is significant potential for products that integrate various assays for clinical research, such as immunotherapy, and assessment of minimal residual disease. During the next three to five years, we expect our R&D initiatives to lead to enhancement of our product line and strengthening of our position in the clinical market.
Manufacturing Advancements: We continuously enhance our assay automation and manufacture reagents stabilizers to reduce the time and cost of performing clinical assays. In March 2026, several manufacturers launched innovative, sample-to-answer, automated systems to enable healthcare professionals in general and oncology laboratories to perform CLIA-certified testing. These systems not only reduce turnaround times, but also improve the cost effectiveness of performing clinical assays. We expect the same trends to continue for other clinical assays. Over the next three to five years, we expect testing to be widely available at major oncology centres and other hospitals.

The challenges facing this market include:

Insufficient Standardization of Clinical Practices: There remains variation in methods for collection and enrichment of circulating tumour cells, and in reporting standards and molecular markers. As of February 2025, there continued to be a lack of interchangeability of assays for various tumour types, particularly for tumour types with low or variable cellular shedding. This variability impedes development of standardized clinical practice and multi-centre studies, as well as poses challenges in determining reimbursement and assessing therapeutic outcome. Low cellular tumour loads can give rise to false-negative results. Epithelial cell adhesion molecule (EpCAM) dependent methods can fail to detect cells that have undergone epithelial-mesenchymal transition. Without improved standards and practices, challenges in the adoption of circulating tumour cell assays will continue for the foreseeable future.
Economic Constraints and Reimbursement Challenges: Compensation for CTC assays are not well established. The cost of the instruments and the specialized personnel required for its performance and interpretation remains a barrier. As of July 2025, several health care systems performed assessment of advanced liquid biopsies, and in the absence of compelling data showing improvements in survival and Diagnostic challenges associated with advanced liquid biopsies will continue for the foreseeable future.
Biology of Circulating Tumour Cells and Sample Handling: Circulating tumour cells are rare, and if captured, challenging to characterize due to biological variability. 2025 Industry Reports on Liquid Biopsies noted that there are several reasons for variable results in a liquid biopsy, including, but not limited to, delays and variations in temperature during sample processing and transport, cellular loss, and heterogenicity among metastatic tumour cells. A sample may not represent all of the metastatic sites, and cells captured in the sample may not be representative of the metastatic cellular population. These uncertainties negatively impact the confidence level of the practitioner. It is expected that during the next 5 years, advances in sample quality and concurrent improvements in multiple assay methodologies will help facilitate the transformation of laboratory diagnostics to the clinical setting.

It is generally anticipated that the global market for circulating tumour cell technology will experience robust growth. The global oncology market is rapidly expanding with advances in personalized medicine. Additionally, liquid biopsy technologies are gaining traction. There are numerous advantages of integrating automated, multiple molecular platforms. Although there are many opportunities and advances in the field, there are equally as many challenges, including cost-prohibitive prices and lack of reimbursement. Many market observers agree that advances in this field are likely to occur in high-level oncology research, rather than in routine clinical care, during the next 5 years.

List of Circulating Tumor Cell Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies circulating tumor cell market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the circulating tumor cell market companies profiled in this report include-

AVIVA Biosciences
Greiner Bio-One International GmbH
IVDiagnostics
BioCEP Ltd
Fluxion Biosciences
Precision for Medicine
Miltenyi Biotec GmbH
Ikonisys
Bio-Techne Corporation
Qiagen NV

Circulating Tumor Cell Market by Segment

The study includes a forecast for the global circulating tumor cell market by product, specimen, application, end use, and region.

Circulating Tumor Cell Market by Product [Value ($B) from 2019 to 2035]:

Kits & Reagents
Blood Collection Tubes
Devices

Circulating Tumor Cell Market by Specimen [Value ($B) from 2019 to 2035]:

Blood
Bone Marrow
Others

Circulating Tumor Cell Market by Application [Value ($B) from 2019 to 2035]:

Research, Clinical
Drug/Therapy Development

Circulating Tumor Cell Market by End Use [Value ($B) from 2019 to 2035]:

Hospital & Clinics
Diagnostic Centers
Research & Academic Institutes

Circulating Tumor Cell Market by Region [Value ($B) from 2019 to 2035]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Circulating Tumor Cell Market

The market for products and services based on circulating tumor cells (CTCs) is transitioning from focusing on their use in prognostic testing to their use in choosing the best cancer treatment and in monitoring cancer treatment. Over the next several years, there is expected to be growth in funding and research collaborations in the area of liquid biopsies and automation of the clinical and laboratory testing of CTCs. According to Lucintel, in the near and medium term, the market will be determined by the level of consistency and reliability, reimbursement, and integration with molecular diagnostic tests.

United States: Various diagnostic companies and several federal agencies have set up or are setting up programs to establish evidence-based standards for liquid biopsy tests. In the United States, the CTC field still largely depends on the Menarini (CellSearch) platform. In 2025, the U.S. FDA launched the Project Catalyst initiative (with 12 oncology partnering diagnostics) to expedite the review of oncology diagnostic tests. The initiative should positively impact the reimbursement and adoption of CTC tests by U.S. hospitals.
China: Investment in biotechnology, particularly in the field of translational medicine, fosters the development of CTC tests. In 2025, the Chinese NMPA (formerly CDE) granted approval to 15 innovative in-vitro diagnostic devices, several of which are in the field of oncology. Chinese CTC tests can be expected to gain wider market acceptance in China.
Germany: Decentralized liquid-biopsy tests are gaining popularity among German cancer centers and diagnostics companies, with CTC tests becoming more prevalent in the context of precision oncology. Funding from the German Federal Ministry of Education and Research in February 2025 (€40 million) for translational cancer research further demonstrates Germany's commitment to funding cancer-related research. Historically, publicly funded research has facilitated the transition of CTC assays from research to clinical practice.
India: Affordable CTC assays are being developed to test breast, lung and colorectal cancers. In April 2025, the Department of Biotechnology of India selected 20 projects in cancer research as part of its translational research programs. Cheaper diagnostic and research tools in India have allowed companies to develop assays and instruments for CTC enumeration.
Japan: Several research studies on various cancers (e.g. gastric, pancreatic, lung, colon and prostate) integrate CTC testing within the framework of liquid biopsies. Japan's commitment to research, combined with an aging population and a growing number of cases of several cancers, will likely allow for the adoption of CTC testing in clinical practice.

Features of the Global Circulating Tumor Cell Market

Market Size Estimates: circulating tumor cell market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
Segmentation Analysis: circulating tumor cell market size by various segments, such as by product, specimen, application, end use, and region in terms of value ($B).
Regional Analysis: circulating tumor cell market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different products, specimen, applications, end uses, and regions for the circulating tumor cell market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the circulating tumor cell market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the circulating tumor cell market by product (kits & reagents, blood collection tubes, and devices), specimen (blood, bone marrow, and others), application (research, clinical and drug/therapy development), end use (hospital & clinics, diagnostic centers, and research & academic institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Circulating Tumor Cell Market by Product

4.1 Overview
4.2 Attractiveness Analysis by Product
4.3 Kits & Reagents : Trends and Forecast 2019 to 2035
4.4 Blood Collection Tubes : Trends and Forecast 2019 to 2035
4.5 Devices : Trends and Forecast 2019 to 2035

5. Global Circulating Tumor Cell Market by Specimen

5.1 Overview
5.2 Attractiveness Analysis by Specimen
5.3 Blood : Trends and Forecast 2019 to 2035
5.4 Bone Marrow : Trends and Forecast 2019 to 2035
5.5 Others : Trends and Forecast 2019 to 2035

6. Global Circulating Tumor Cell Market by Application

6.1 Overview
6.2 Attractiveness Analysis by Application
6.3 Research, Clinical : Trends and Forecast 2019 to 2035
6.4 Drug/Therapy Development : Trends and Forecast 2019 to 2035

7. Global Circulating Tumor Cell Market by End Use

7.1 Overview
7.2 Attractiveness Analysis by End Use
7.3 Hospital & Clinics : Trends and Forecast 2019 to 2035
7.4 Diagnostic Centers : Trends and Forecast 2019 to 2035
7.5 Research & Academic Institutes : Trends and Forecast 2019 to 2035

8. Regional Analysis

8.1 Overview
8.2 Global Circulating Tumor Cell Market by Region

9. North American Circulating Tumor Cell Market

9.1 Overview
9.2 North American Circulating Tumor Cell Market by Product
9.3 North American Circulating Tumor Cell Market by End Use
9.4 The United States Circulating Tumor Cell Market
9.5 Canadian Circulating Tumor Cell Market
9.6 Mexican Circulating Tumor Cell Market

10. European Circulating Tumor Cell Market

10.1 Overview
10.2 European Circulating Tumor Cell Market by Product
10.3 European Circulating Tumor Cell Market by End Use
10.4 German Circulating Tumor Cell Market
10.5 French Circulating Tumor Cell Market
10.6 Italian Circulating Tumor Cell Market
10.7 Spanish Circulating Tumor Cell Market
10.8 The United Kingdom Circulating Tumor Cell Market

11. APAC Circulating Tumor Cell Market

11.1 Overview
11.2 APAC Circulating Tumor Cell Market by Product
11.3 APAC Circulating Tumor Cell Market by End Use
11.4 Chinese Circulating Tumor Cell Market
11.5 Indian Circulating Tumor Cell Market
11.6 Japanese Circulating Tumor Cell Market
11.7 South Korean Circulating Tumor Cell Market
11.8 Indonesian Circulating Tumor Cell Market

12. ROW Circulating Tumor Cell Market

12.1 Overview
12.2 ROW Circulating Tumor Cell Market by Product
12.3 ROW Circulating Tumor Cell Market by End Use
12.4 Middle Eastern Circulating Tumor Cell Market
12.5 South American Circulating Tumor Cell Market
12.6 African Circulating Tumor Cell Market

13. Competitor Analysis

13.1 Product Portfolio Analysis
13.2 Operational Integration
13.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

14.1 Value Chain Analysis
14.2 Growth Opportunity Analysis
- 14.2.1 Growth Opportunity by Product
- 14.2.2 Growth Opportunity by Specimen
- 14.2.3 Growth Opportunity by Application
- 14.2.4 Growth Opportunity by End Use
14.3 Emerging Trends in the Global Circulating Tumor Cell Market
14.4 Strategic Analysis
- 14.4.1 New Product Development
- 14.4.2 Certification and Licensing
- 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

15.1 Competitive Analysis Overview
15.2 AVIVA Biosciences
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.3 Greiner Bio-One International GmbH
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.4 IVDiagnostics
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.5 BioCEP Ltd
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.6 Fluxion Biosciences
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.7 Precision for Medicine
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.8 Miltenyi Biotec GmbH
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.9 Ikonisys
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.10 Bio-Techne Corporation
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
15.11 Qiagen NV.
- Company Overview
- Circulating Tumor Cell Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

16. Appendix

16.1 List of Figures
16.2 List of Tables
16.3 Research Methodology
16.4 Disclaimer
16.5 Copyright
16.6 Abbreviations and Technical Units
16.7 About Us
16.8 Contact Us

簡介目錄圖表

List of Figures

Figure 1.1: Trends and Forecast for the Global Circulating Tumor Cell Market
Figure 2.1: Usage of Circulating Tumor Cell Market
Figure 2.2: Classification of the Global Circulating Tumor Cell Market
Figure 2.3: Supply Chain of the Global Circulating Tumor Cell Market
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 3.19: Driver and Challenges of the Circulating Tumor Cell Market
Figure 4.1: Global Circulating Tumor Cell Market by Product in 2019, 2026, and 2035
Figure 4.2: Trends of the Global Circulating Tumor Cell Market ($B) by Product
Figure 4.3: Forecast for the Global Circulating Tumor Cell Market ($B) by Product
Figure 4.4: Trends and Forecast for Kits & Reagents in the Global Circulating Tumor Cell Market (2019-2035)
Figure 4.5: Trends and Forecast for Blood Collection Tubes in the Global Circulating Tumor Cell Market (2019-2035)
Figure 4.6: Trends and Forecast for Devices in the Global Circulating Tumor Cell Market (2019-2035)
Figure 5.1: Global Circulating Tumor Cell Market by Specimen in 2019, 2026, and 2035
Figure 5.2: Trends of the Global Circulating Tumor Cell Market ($B) by Specimen
Figure 5.3: Forecast for the Global Circulating Tumor Cell Market ($B) by Specimen
Figure 5.4: Trends and Forecast for Blood in the Global Circulating Tumor Cell Market (2019-2035)
Figure 5.5: Trends and Forecast for Bone Marrow in the Global Circulating Tumor Cell Market (2019-2035)
Figure 5.6: Trends and Forecast for Others in the Global Circulating Tumor Cell Market (2019-2035)
Figure 6.1: Global Circulating Tumor Cell Market by Application in 2019, 2026, and 2035
Figure 6.2: Trends of the Global Circulating Tumor Cell Market ($B) by Application
Figure 6.3: Forecast for the Global Circulating Tumor Cell Market ($B) by Application
Figure 6.4: Trends and Forecast for Research, Clinical in the Global Circulating Tumor Cell Market (2019-2035)
Figure 6.5: Trends and Forecast for Drug/Therapy Development in the Global Circulating Tumor Cell Market (2019-2035)
Figure 7.1: Global Circulating Tumor Cell Market by End Use in 2019, 2026, and 2035
Figure 7.2: Trends of the Global Circulating Tumor Cell Market ($B) by End Use
Figure 7.3: Forecast for the Global Circulating Tumor Cell Market ($B) by End Use
Figure 7.4: Trends and Forecast for Hospital & Clinics in the Global Circulating Tumor Cell Market (2019-2035)
Figure 7.5: Trends and Forecast for Diagnostic Centers in the Global Circulating Tumor Cell Market (2019-2035)
Figure 7.6: Trends and Forecast for Research & Academic Institutes in the Global Circulating Tumor Cell Market (2019-2035)
Figure 8.1: Trends of the Global Circulating Tumor Cell Market ($B) by Region (2019-2026)
Figure 8.2: Forecast for the Global Circulating Tumor Cell Market ($B) by Region (2027-2035)
Figure 9.1: Trends and Forecast for the North American Circulating Tumor Cell Market (2019-2035)
Figure 9.2: North American Circulating Tumor Cell Market by Product in 2019, 2026, and 2035
Figure 9.3: Trends of the North American Circulating Tumor Cell Market ($B) by Product (2019-2026)
Figure 9.4: Forecast for the North American Circulating Tumor Cell Market ($B) by Product (2027-2035)
Figure 9.5: North American Circulating Tumor Cell Market by Specimen in 2019, 2026, and 2035
Figure 9.6: Trends of the North American Circulating Tumor Cell Market ($B) by Specimen (2019-2026)
Figure 9.7: Forecast for the North American Circulating Tumor Cell Market ($B) by Specimen (2027-2035)
Figure 9.8: North American Circulating Tumor Cell Market by Application in 2019, 2026, and 2035
Figure 9.9: Trends of the North American Circulating Tumor Cell Market ($B) by Application (2019-2026)
Figure 9.10: Forecast for the North American Circulating Tumor Cell Market ($B) by Application (2027-2035)
Figure 9.11: North American Circulating Tumor Cell Market by End Use in 2019, 2026, and 2035
Figure 9.12: Trends of the North American Circulating Tumor Cell Market ($B) by End Use (2019-2026)
Figure 9.13: Forecast for the North American Circulating Tumor Cell Market ($B) by End Use (2027-2035)
Figure 9.14: Trends and Forecast for the United States Circulating Tumor Cell Market ($B) (2019-2035)
Figure 9.15: Trends and Forecast for the Mexican Circulating Tumor Cell Market ($B) (2019-2035)
Figure 9.16: Trends and Forecast for the Canadian Circulating Tumor Cell Market ($B) (2019-2035)
Figure 10.1: Trends and Forecast for the European Circulating Tumor Cell Market (2019-2035)
Figure 10.2: European Circulating Tumor Cell Market by Product in 2019, 2026, and 2035
Figure 10.3: Trends of the European Circulating Tumor Cell Market ($B) by Product (2019-2026)
Figure 10.4: Forecast for the European Circulating Tumor Cell Market ($B) by Product (2027-2035)
Figure 10.5: European Circulating Tumor Cell Market by Specimen in 2019, 2026, and 2035
Figure 10.6: Trends of the European Circulating Tumor Cell Market ($B) by Specimen (2019-2026)
Figure 10.7: Forecast for the European Circulating Tumor Cell Market ($B) by Specimen (2027-2035)
Figure 10.8: European Circulating Tumor Cell Market by Application in 2019, 2026, and 2035
Figure 10.9: Trends of the European Circulating Tumor Cell Market ($B) by Application (2019-2026)
Figure 10.10: Forecast for the European Circulating Tumor Cell Market ($B) by Application (2027-2035)
Figure 10.11: European Circulating Tumor Cell Market by End Use in 2019, 2026, and 2035
Figure 10.12: Trends of the European Circulating Tumor Cell Market ($B) by End Use (2019-2026)
Figure 10.13: Forecast for the European Circulating Tumor Cell Market ($B) by End Use (2027-2035)
Figure 10.14: Trends and Forecast for the German Circulating Tumor Cell Market ($B) (2019-2035)
Figure 10.15: Trends and Forecast for the French Circulating Tumor Cell Market ($B) (2019-2035)
Figure 10.16: Trends and Forecast for the Spanish Circulating Tumor Cell Market ($B) (2019-2035)
Figure 10.17: Trends and Forecast for the Italian Circulating Tumor Cell Market ($B) (2019-2035)
Figure 10.18: Trends and Forecast for the United Kingdom Circulating Tumor Cell Market ($B) (2019-2035)
Figure 11.1: Trends and Forecast for the APAC Circulating Tumor Cell Market (2019-2035)
Figure 11.2: APAC Circulating Tumor Cell Market by Product in 2019, 2026, and 2035
Figure 11.3: Trends of the APAC Circulating Tumor Cell Market ($B) by Product (2019-2026)
Figure 11.4: Forecast for the APAC Circulating Tumor Cell Market ($B) by Product (2027-2035)
Figure 11.5: APAC Circulating Tumor Cell Market by Specimen in 2019, 2026, and 2035
Figure 11.6: Trends of the APAC Circulating Tumor Cell Market ($B) by Specimen (2019-2026)
Figure 11.7: Forecast for the APAC Circulating Tumor Cell Market ($B) by Specimen (2027-2035)
Figure 11.8: APAC Circulating Tumor Cell Market by Application in 2019, 2026, and 2035
Figure 11.9: Trends of the APAC Circulating Tumor Cell Market ($B) by Application (2019-2026)
Figure 11.10: Forecast for the APAC Circulating Tumor Cell Market ($B) by Application (2027-2035)
Figure 11.11: APAC Circulating Tumor Cell Market by End Use in 2019, 2026, and 2035
Figure 11.12: Trends of the APAC Circulating Tumor Cell Market ($B) by End Use (2019-2026)
Figure 11.13: Forecast for the APAC Circulating Tumor Cell Market ($B) by End Use (2027-2035)
Figure 11.14: Trends and Forecast for the Japanese Circulating Tumor Cell Market ($B) (2019-2035)
Figure 11.15: Trends and Forecast for the Indian Circulating Tumor Cell Market ($B) (2019-2035)
Figure 11.16: Trends and Forecast for the Chinese Circulating Tumor Cell Market ($B) (2019-2035)
Figure 11.17: Trends and Forecast for the South Korean Circulating Tumor Cell Market ($B) (2019-2035)
Figure 11.18: Trends and Forecast for the Indonesian Circulating Tumor Cell Market ($B) (2019-2035)
Figure 12.1: Trends and Forecast for the ROW Circulating Tumor Cell Market (2019-2035)
Figure 12.2: ROW Circulating Tumor Cell Market by Product in 2019, 2026, and 2035
Figure 12.3: Trends of the ROW Circulating Tumor Cell Market ($B) by Product (2019-2026)
Figure 12.4: Forecast for the ROW Circulating Tumor Cell Market ($B) by Product (2027-2035)
Figure 12.5: ROW Circulating Tumor Cell Market by Specimen in 2019, 2026, and 2035
Figure 12.6: Trends of the ROW Circulating Tumor Cell Market ($B) by Specimen (2019-2026)
Figure 12.7: Forecast for the ROW Circulating Tumor Cell Market ($B) by Specimen (2027-2035)
Figure 12.8: ROW Circulating Tumor Cell Market by Application in 2019, 2026, and 2035
Figure 12.9: Trends of the ROW Circulating Tumor Cell Market ($B) by Application (2019-2026)
Figure 12.10: Forecast for the ROW Circulating Tumor Cell Market ($B) by Application (2027-2035)
Figure 12.11: ROW Circulating Tumor Cell Market by End Use in 2019, 2026, and 2035
Figure 12.12: Trends of the ROW Circulating Tumor Cell Market ($B) by End Use (2019-2026)
Figure 12.13: Forecast for the ROW Circulating Tumor Cell Market ($B) by End Use (2027-2035)
Figure 12.14: Trends and Forecast for the Middle Eastern Circulating Tumor Cell Market ($B) (2019-2035)
Figure 12.15: Trends and Forecast for the South American Circulating Tumor Cell Market ($B) (2019-2035)
Figure 12.16: Trends and Forecast for the African Circulating Tumor Cell Market ($B) (2019-2035)
Figure 13.1: Porter's Five Forces Analysis of the Global Circulating Tumor Cell Market
Figure 13.2: Market Share (%) of Top Players in the Global Circulating Tumor Cell Market (2026)
Figure 14.1: Growth Opportunities for the Global Circulating Tumor Cell Market by Product
Figure 14.2: Growth Opportunities for the Global Circulating Tumor Cell Market by Specimen
Figure 14.3: Growth Opportunities for the Global Circulating Tumor Cell Market by Application
Figure 14.4: Growth Opportunities for the Global Circulating Tumor Cell Market by End Use
Figure 14.5: Growth Opportunities for the Global Circulating Tumor Cell Market by Region
Figure 14.6: Emerging Trends in the Global Circulating Tumor Cell Market

List of Tables

Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Circulating Tumor Cell Market by Product, Specimen, Application, and End Use
Table 1.2: Attractiveness Analysis for the Circulating Tumor Cell Market by Region
Table 1.3: Global Circulating Tumor Cell Market Parameters and Attributes
Table 3.1: Trends of the Global Circulating Tumor Cell Market (2019-2026)
Table 3.2: Forecast for the Global Circulating Tumor Cell Market (2027-2035)
Table 4.1: Attractiveness Analysis for the Global Circulating Tumor Cell Market by Product
Table 4.2: Market Size and CAGR of Various Product in the Global Circulating Tumor Cell Market (2019-2026)
Table 4.3: Market Size and CAGR of Various Product in the Global Circulating Tumor Cell Market (2027-2035)
Table 4.4: Trends of Kits & Reagents in the Global Circulating Tumor Cell Market (2019-2026)
Table 4.5: Forecast for Kits & Reagents in the Global Circulating Tumor Cell Market (2027-2035)
Table 4.6: Trends of Blood Collection Tubes in the Global Circulating Tumor Cell Market (2019-2026)
Table 4.7: Forecast for Blood Collection Tubes in the Global Circulating Tumor Cell Market (2027-2035)
Table 4.8: Trends of Devices in the Global Circulating Tumor Cell Market (2019-2026)
Table 4.9: Forecast for Devices in the Global Circulating Tumor Cell Market (2027-2035)
Table 5.1: Attractiveness Analysis for the Global Circulating Tumor Cell Market by Specimen
Table 5.2: Market Size and CAGR of Various Specimen in the Global Circulating Tumor Cell Market (2019-2026)
Table 5.3: Market Size and CAGR of Various Specimen in the Global Circulating Tumor Cell Market (2027-2035)
Table 5.4: Trends of Blood in the Global Circulating Tumor Cell Market (2019-2026)
Table 5.5: Forecast for Blood in the Global Circulating Tumor Cell Market (2027-2035)
Table 5.6: Trends of Bone Marrow in the Global Circulating Tumor Cell Market (2019-2026)
Table 5.7: Forecast for Bone Marrow in the Global Circulating Tumor Cell Market (2027-2035)
Table 5.8: Trends of Others in the Global Circulating Tumor Cell Market (2019-2026)
Table 5.9: Forecast for Others in the Global Circulating Tumor Cell Market (2027-2035)
Table 6.1: Attractiveness Analysis for the Global Circulating Tumor Cell Market by Application
Table 6.2: Market Size and CAGR of Various Application in the Global Circulating Tumor Cell Market (2019-2026)
Table 6.3: Market Size and CAGR of Various Application in the Global Circulating Tumor Cell Market (2027-2035)
Table 6.4: Trends of Research, Clinical in the Global Circulating Tumor Cell Market (2019-2026)
Table 6.5: Forecast for Research, Clinical in the Global Circulating Tumor Cell Market (2027-2035)
Table 6.6: Trends of Drug/Therapy Development in the Global Circulating Tumor Cell Market (2019-2026)
Table 6.7: Forecast for Drug/Therapy Development in the Global Circulating Tumor Cell Market (2027-2035)
Table 7.1: Attractiveness Analysis for the Global Circulating Tumor Cell Market by End Use
Table 7.2: Market Size and CAGR of Various End Use in the Global Circulating Tumor Cell Market (2019-2026)
Table 7.3: Market Size and CAGR of Various End Use in the Global Circulating Tumor Cell Market (2027-2035)
Table 7.4: Trends of Hospital & Clinics in the Global Circulating Tumor Cell Market (2019-2026)
Table 7.5: Forecast for Hospital & Clinics in the Global Circulating Tumor Cell Market (2027-2035)
Table 7.6: Trends of Diagnostic Centers in the Global Circulating Tumor Cell Market (2019-2026)
Table 7.7: Forecast for Diagnostic Centers in the Global Circulating Tumor Cell Market (2027-2035)
Table 7.8: Trends of Research & Academic Institutes in the Global Circulating Tumor Cell Market (2019-2026)
Table 7.9: Forecast for Research & Academic Institutes in the Global Circulating Tumor Cell Market (2027-2035)
Table 8.1: Market Size and CAGR of Various Regions in the Global Circulating Tumor Cell Market (2019-2026)
Table 8.2: Market Size and CAGR of Various Regions in the Global Circulating Tumor Cell Market (2027-2035)
Table 9.1: Trends of the North American Circulating Tumor Cell Market (2019-2026)
Table 9.2: Forecast for the North American Circulating Tumor Cell Market (2027-2035)
Table 9.3: Market Size and CAGR of Various Product in the North American Circulating Tumor Cell Market (2019-2026)
Table 9.4: Market Size and CAGR of Various Product in the North American Circulating Tumor Cell Market (2027-2035)
Table 9.5: Market Size and CAGR of Various Specimen in the North American Circulating Tumor Cell Market (2019-2026)
Table 9.6: Market Size and CAGR of Various Specimen in the North American Circulating Tumor Cell Market (2027-2035)
Table 9.7: Market Size and CAGR of Various Application in the North American Circulating Tumor Cell Market (2019-2026)
Table 9.8: Market Size and CAGR of Various Application in the North American Circulating Tumor Cell Market (2027-2035)
Table 9.9: Market Size and CAGR of Various End Use in the North American Circulating Tumor Cell Market (2019-2026)
Table 9.10: Market Size and CAGR of Various End Use in the North American Circulating Tumor Cell Market (2027-2035)
Table 9.11: Trends and Forecast for the United States Circulating Tumor Cell Market (2019-2035)
Table 9.12: Trends and Forecast for the Mexican Circulating Tumor Cell Market (2019-2035)
Table 9.13: Trends and Forecast for the Canadian Circulating Tumor Cell Market (2019-2035)
Table 10.1: Trends of the European Circulating Tumor Cell Market (2019-2026)
Table 10.2: Forecast for the European Circulating Tumor Cell Market (2027-2035)
Table 10.3: Market Size and CAGR of Various Product in the European Circulating Tumor Cell Market (2019-2026)
Table 10.4: Market Size and CAGR of Various Product in the European Circulating Tumor Cell Market (2027-2035)
Table 10.5: Market Size and CAGR of Various Specimen in the European Circulating Tumor Cell Market (2019-2026)
Table 10.6: Market Size and CAGR of Various Specimen in the European Circulating Tumor Cell Market (2027-2035)
Table 10.7: Market Size and CAGR of Various Application in the European Circulating Tumor Cell Market (2019-2026)
Table 10.8: Market Size and CAGR of Various Application in the European Circulating Tumor Cell Market (2027-2035)
Table 10.9: Market Size and CAGR of Various End Use in the European Circulating Tumor Cell Market (2019-2026)
Table 10.10: Market Size and CAGR of Various End Use in the European Circulating Tumor Cell Market (2027-2035,)
Table 10.11: Trends and Forecast for the German Circulating Tumor Cell Market (2019-2035)
Table 10.12: Trends and Forecast for the French Circulating Tumor Cell Market (2019-2035)
Table 10.13: Trends and Forecast for the Spanish Circulating Tumor Cell Market (2019-2035)
Table 10.14: Trends and Forecast for the Italian Circulating Tumor Cell Market (2019-2035)
Table 10.15: Trends and Forecast for the United Kingdom Circulating Tumor Cell Market (2019-2035)
Table 11.1: Trends of the APAC Circulating Tumor Cell Market (2019-2026)
Table 11.2: Forecast for the APAC Circulating Tumor Cell Market (2027-2035)
Table 11.3: Market Size and CAGR of Various Product in the APAC Circulating Tumor Cell Market (2019-2026)
Table 11.4: Market Size and CAGR of Various Product in the APAC Circulating Tumor Cell Market (2027-2035)
Table 11.5: Market Size and CAGR of Various Specimen in the APAC Circulating Tumor Cell Market (2019-2026)
Table 11.6: Market Size and CAGR of Various Specimen in the APAC Circulating Tumor Cell Market (2027-2035)
Table 11.7: Market Size and CAGR of Various Application in the APAC Circulating Tumor Cell Market (2019-2026)
Table 11.8: Market Size and CAGR of Various Application in the APAC Circulating Tumor Cell Market (2027-2035)
Table 11.9: Market Size and CAGR of Various End Use in the APAC Circulating Tumor Cell Market (2019-2026)
Table 11.10: Market Size and CAGR of Various End Use in the APAC Circulating Tumor Cell Market (2027-2035)
Table 11.11: Trends and Forecast for the Japanese Circulating Tumor Cell Market (2019-2035)
Table 11.12: Trends and Forecast for the Indian Circulating Tumor Cell Market (2019-2035)
Table 11.13: Trends and Forecast for the Chinese Circulating Tumor Cell Market (2019-2035)
Table 11.14: Trends and Forecast for the South Korean Circulating Tumor Cell Market (2019-2035)
Table 11.15: Trends and Forecast for the Indonesian Circulating Tumor Cell Market (2019-2035)
Table 12.1: Trends of the ROW Circulating Tumor Cell Market (2019-2026)
Table 12.2: Forecast for the ROW Circulating Tumor Cell Market (2027-2035)
Table 12.3: Market Size and CAGR of Various Product in the ROW Circulating Tumor Cell Market (2019-2026)
Table 12.4: Market Size and CAGR of Various Product in the ROW Circulating Tumor Cell Market (2027-2035)
Table 12.5: Market Size and CAGR of Various Specimen in the ROW Circulating Tumor Cell Market (2019-2026)
Table 12.6: Market Size and CAGR of Various Specimen in the ROW Circulating Tumor Cell Market (2027-2035)
Table 12.7: Market Size and CAGR of Various Application in the ROW Circulating Tumor Cell Market (2019-2026)
Table 12.8: Market Size and CAGR of Various Application in the ROW Circulating Tumor Cell Market (2027-2035)
Table 12.9: Market Size and CAGR of Various End Use in the ROW Circulating Tumor Cell Market (2019-2026)
Table 12.10: Market Size and CAGR of Various End Use in the ROW Circulating Tumor Cell Market (2027-2035)
Table 12.11: Trends and Forecast for the Middle Eastern Circulating Tumor Cell Market (2019-2035)
Table 12.12: Trends and Forecast for the South American Circulating Tumor Cell Market (2019-2035)
Table 12.13: Trends and Forecast for the African Circulating Tumor Cell Market (2019-2035)
Table 13.1: Product Mapping of Circulating Tumor Cell Suppliers Based on Segments
Table 13.2: Operational Integration of Circulating Tumor Cell Manufacturers
Table 13.3: Rankings of Suppliers Based on Circulating Tumor Cell Revenue
Table 14.1: New Product Launches by Major Circulating Tumor Cell Producers (2019-2026)
Table 14.2: Certification Acquired by Major Competitor in the Global Circulating Tumor Cell Market